Evidence map›Paper›PMID 39509657›Full record

ArticleJCO global oncology2024

Assessment of the Clinicopathologic Characteristics and Survival Rates of Colorectal Cancer Among Syrian Refugees and Turkish Population in Gaziantep Province.

Canan Karan, İlker Nihat Okten, Oğuzhan Kesen, Atalay Çelikyürek, Fatih Teker, Şuayib Yalçın

Abstract read
In one paragraph

Article in JCO global oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Canan KaranDepartment of Oncology, Gaziantep Liv Hospital, Gaziantep, Turkey.ORCID 0000-0002-1293-2046
İlker Nihat OktenDepartment of Oncology, Istanbul Oncology Hospital, Istanbul, Turkey.ORCID 0000-0003-2360-3392
Oğuzhan KesenDepartment of Oncology, Faculty of Medicine Rize, Recep Tayyip Erdogan University, Rize, Turkey.
Atalay ÇelikyürekDepartment of Public Health, Faculty of Medicine, Pamukkale University, Denizli, Turkey.ORCID 0000-0001-9731-8880
Fatih TekerDepartment of Oncology, Gaziantep Liv Hospital, Gaziantep, Turkey.ORCID 0000-0003-4693-6587
Şuayib YalçınDepartment of Oncology, Faculty of Medicine, Hacettepe University, Ankara, Turkey.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeSyrian refugees (SRs) have had difficulties in the diagnosis, treatment, and follow-up of chronic diseases, such as cancer, because of the conflict in the region. The cancer diagnosis and treatment process of SR are also a matter of curiosity. We aimed to compare the demographic characteristics and survival outcome data of SRs and Turkish citizens (TCs), and colorectal cancer (CRC) is one of the most common cancer types seen with similar frequency globally. MATERIALS AND

methodsA total of 421 patients with CRC were included. Overall survival (OS) was estimated using the Kaplan-Meier method, and the log-rank test was used for comparison. Patient demographic data were compared using the Pearson Chi-square test and independent

resultsIn total, 421 patients (282 TCs and 139 SRs) were included in this study. The mean age was 52.9 ± 14.3 years for the entire population: 55.3 ± 14.1 years for TCs and 47.9 ± 13.4 years for SRs. Forty (29%) SRs and 60 (21.4%) TCs had de novo metastatic disease (

conclusionThe survival rate was lower in the SR group. Since CRC is also common among refugees, developing and implementing methods to improve the welfare of vulnerable populations is necessary.

Indexed as

Colorectal NeoplasmsRefugeesAdultAgedFemaleHumansMaleMiddle AgedSurvival RateSyriaTurkey

Identifiers

PMID39509657
PMCPMC11583350

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.